share_log

Exact Sciences | 10-Q: Q2 2024 Earnings Report

Exact Sciences | 10-Q: Q2 2024 Earnings Report

精密科學 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/31 14:11

Moomoo AI 已提取核心訊息

Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.
Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.
精密科學報告了2024年第二季度強勁的財務業績，營業收入同比增長12.4%，達到69930萬，主要得益於篩查營業收入增長14.9%，達53160萬，以及精準腫瘤學營業收入增長6.7%，達到16770萬。該公司在本季度首次完成超過100萬次的Cologuard測試，同時運營虧損大幅收窄至2630萬，較去年同期的7690萬有顯著改善。公司持續推進其產品管道，FDA正在審查Cologuard Plus的上市前批准申請，預計將在2024年底做出決定。精密科學還在AACR會議上展示了其ASCEND-2多癌症篩查研究的有前景的數據，並以4500萬獲得TwinStrand的無細胞核酸測序科技的獨家許可。截至2024年6月30日，公司現金及投資總額爲94680萬。該公司發行了62070萬的1.75%可轉換債券，至2031年到期，獲得淨收益25980萬。2024年上半年運營現金流爲2480萬，管理層對未來至少12個月的當前運營資金表達了信懇智能。
精密科學報告了2024年第二季度強勁的財務業績，營業收入同比增長12.4%，達到69930萬，主要得益於篩查營業收入增長14.9%，達53160萬，以及精準腫瘤學營業收入增長6.7%，達到16770萬。該公司在本季度首次完成超過100萬次的Cologuard測試，同時運營虧損大幅收窄至2630萬，較去年同期的7690萬有顯著改善。公司持續推進其產品管道，FDA正在審查Cologuard Plus的上市前批准申請，預計將在2024年底做出決定。精密科學還在AACR會議上展示了其ASCEND-2多癌症篩查研究的有前景的數據，並以4500萬獲得TwinStrand的無細胞核酸測序科技的獨家許可。截至2024年6月30日，公司現金及投資總額爲94680萬。該公司發行了62070萬的1.75%可轉換債券，至2031年到期，獲得淨收益25980萬。2024年上半年運營現金流爲2480萬，管理層對未來至少12個月的當前運營資金表達了信懇智能。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    燃石醫學
    BNR
    -- 6.940
    Neuronetics
    STIM
    -- 4.360
    Personalis
    PSNL
    -- 5.510
    OncoCyte
    OCX
    -- 2.5600
    恩佐生化
    ENZ
    -- 0.545
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。